Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.
New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.
Many women at high risk for breast cancer are foregoing tamoxifen, the first FDA-approved drug for prevention of breast cancer, due to concerns about side effects, increased risk of other cancers, and lack of information, a new study by researchers in Boston shows. The study was published in the December 14 in the Journal of Clinical Oncology.
Osteoarthritis (OA) of the knee, a chronic inflammatory disease marked by cartilage degradation and bone abnormalities, is a leading cause of disability among elderly people in the United States.
The largest North American breast cancer prevention trial ever undertaken, the Study of Tamoxifen and Raloxifene (STAR), reached its goal of enrolling 19,000 women to the trial in June 2004, a month earlier than originally expected.
Research in monkeys suggests the possibility that stress may increase risk for the most common type of uterine cancer, according to a report from Wake Forest University Baptist Medical Center.
Newest research findings were presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction. SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer.
Leaders of North America's largest-ever breast cancer prevention trial, the Study of Tamoxifen and Raloxifene (STAR), are striving to reach a major milestone this summer: the enrollment of the study's 19,000th — and final — participant.